STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)

Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer

Trial Details

NCT ID
NCT05716516
Phase
PHASE2
Sponsor
Dartmouth-Hitchcock Medical Center
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Estradiol
Locations (sample)
  • Lebanon, New Hampshire, United States|43.64229,-72.25176

Key Eligibility Criteria

  • Post-menopausal women with ER+ breast cancer.
  • Metastatic or locoregional recurrence not amenable to treatment with curative
  • Received ≥1 prior line of endocrine-based therapy (e.g., including tamoxifen, aromatase inhibitors, fulvestrant, or combinations) in the advanced/m…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →